featured
Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed CAR T-Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b/2 Open-Label Study
Lancet 2021 Jun 24;[EPub Ahead of Print], JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak, M Agha, AD Cohen, AK Stewart, P Hari, M Htut, A Lesokhin, A Deol, NC Munshi, E O'Donnell, D Avigan, I Singh, E Zudaire, TM Yeh, AJ Allred, Y Olyslager, A Banerjee, CC Jackson, JD Goldberg, JM Schecter, W Deraedt, SH Zhuang, J Infante, D Geng, X Wu, MJ Carrasco-Alfonso, M Akram, F Hossain, S Rizvi, F Fan, Y Lin, T Martin, S JagannathFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.